Anti-fibrillogenic and fibril-destabilizing activities of anti-Parkinsonian agents for α-synuclein fibrils in vitro
✍ Scribed by Kenjiro Ono; Mie Hirohata; Masahito Yamada
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 614 KB
- Volume
- 85
- Category
- Article
- ISSN
- 0360-4012
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
The aggregation of alpha‐synuclein (αS) in the brain has been implicated as a critical step in the development of Lewy body diseases (LBD) and multiple system atrophy (MSA). Among the antioxidant strategies proposed, increasing evidence points to the possibility of achieving neuroprotection by dopamine agonists, as well as monoamine oxidase B inhibitors. We showed previously that the anti‐Parkinsonian agents dose‐dependently inhibited β‐amyloid fibrils (fAβ)(1–40) and fAβ(1–42) formation as well as destabilized preformed fAβs. Using fluorescence spectroscopy with thioflavin S, electron microscopy, and atomic force microscopy, we examined the effects of anti‐Parkinsonian agents, selegiline, dopamine, pergolide, bromocriptine, and trihexyphenidyl on the formation of αS fibrils (fαS) and on preformed fαS. All molecules except for trihexyphenidyl, dose‐dependently inhibited the formation of fαS. Moreover, these molecules dose‐dependently destabilized preformed fαS. The overall activity of the molecules examined was in the order of: selegiline = dopamine > pergolide > bromocriptine. These agents and other compounds related structurally could be key molecules for the development of therapeutics for LBD and MSA. © 2007 Wiley‐Liss, Inc.